NORLUX Neuro-Oncology Laboratory
NORLUX represents a state-of-the art multidisciplinary research group with a critical mass of competitive scientists in neuro-oncology research.
activities
We aim to improve the treatment options for malignant brain tumors, with a focus on diffuse gliomas. With a radically translational approach to research, we work with patient samples and innovative patient-derived preclinical model systems that recapitulate the patient tumor. Our research investigates the cellular and molecular basis of gliomas, their capacity to invade the normal brain and escape therapy. Special areas of interests are tumor plasticity, tumor heterogeneity, tumor metabolism, immuno-oncology and pharmacogenomics.
projects
- Glioma patient avatars for personalized medicine
- Immuno-competent tumor organoids
- Personalized medicine and pharmacogenomics
- Glioblastoma heterogeneity, plasticity and tumor-microenvironment interactions
- IDH mutant glioma metabolism
- Novel regulators of glioma invasion
- Epigenetics, regulatory RNAs and functional genomics
- Harnessing endogenous RTK inhibitors for anti-cancer treatment
Anna
Golebiewska
Golebiewska
Funding Support
Projects & clinical trials
Featured team members
-
Magretta
Adiamah Postdoctoral Fellow -
Virginie
Baus Laboratory Technician -
Monika
Dieterle Research Engineer -
Marta
Domenech Visiting Researcher -
Claire
Dording Laboratory Technician -
Luca
Ermini Scientist -
Sabrina
Fritah Scientist -
Anna
Golebiewska Group Leader
Scientific publications
-
Advancing preclinical cancer models to assess clinically relevant outcomes – 10/03/2023
-
How to move a ”fried egg” – membrane blebbing in oligodendrogliomas – 14/02/2023
-
Stabilization of Stochastic Dynamical Systems of a Random Structure with Markov Switches and Poisson Perturbations – 01/02/2023
-
Molecular Identity Changes of Tumor-Associated Macrophages and Microglia After Magnetic Resonance Imaging–Guided Focused Ultrasound–Induced Blood–Brain Barrier Opening in a Mouse Glioblastoma Model – 01/01/2023
-
Author Correction – 26/01/2023
-
Formate Promotes Invasion and Metastasis by Activating Fatty Acid Synthesis and Matrix Metalloproteinases – 23/01/2023
-
PKM2 diverts glycolytic flux in dependence on formate overflow – 23/01/2023
-
EANO guideline on rational molecular testing of gliomas, glioneuronal and neuronal tumors in adults for targeted therapy selection – 12/01/2023
-
Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs) – 24/12/2022
-
Stabilization of stochastic dynamical systems of a random structure with Markov switches and Poisson perturbations – 15/12/2022
Related News
-
Four LIH PhD Students awarded the Pelican Grant
-
Submit to the new BMC Cancer pre-clinical model collection
-
Allergies, an ally against cancer?
-
NORLUX Group recognized at the second national 3R Symposium
-
NORLUX researcher featured by Research Luxembourg
-
NORLUX scientist shines at EuroPDX conference
-
Innovation Means Hope: DIOMEDES – a better outlook for Glioblastoma patients
-
Anna Golebiewska featured on SciLux podcast
-
Masters of Disguise: New tactics in the hunt for shapeshifting cancers
-
FNR Awards 2021: LIH researchers shine at centre-stage
-
Congratulations to Yahaya Yabo for winning the LuxDoc 3 Minute thesis competition in the category ‘People’s Choice Prize’!
-
Towards personalised treatment of recurrent brain tumours
-
New insights into Glioblastoma invasiveness
-
Advancing personalised cancer treatment through patient “avatars”
-
Advancing personalised cancer treatment through patient “avatars”
-
Special Issue ‘Resistance Mechanisms in Malignant Brain Tumors’ in Cancers
-
Simone Niclou on the list of ‘100 women for your board of directors’
-
Best Oral Talk Award for Mohamad Sarmini at Télévie Researcher’s day
-
Pelican grant to support training and mobility for glioblastoma research project
-
Best preclinical oral presentation award for Anna Golebiewska at EANO 2019
